Molecular targeted and systemic therapy for intrahepatic cholangiocarcinoma: a multi-disciplinary approach

Katiuscha Merath, Ankur Tiwari, Alexander A. Parikh, Timothy M. Pawlik

Research output: Contribution to journalReview articlepeer-review

Abstract

Most patients with intrahepatic cholangiocarcinoma (ICC) are diagnosed with advanced disease. For individuals with resectable tumors, R0 resection with lymphadenectomy is the best potentially curative-intent treatment. After resection, adjuvant therapy with capecitabine is the current standard of care. For patients with unresectable or distant metastatic disease, doublet chemotherapy with gemcitabine and cisplatin is the most utilized first-line regimen, but recent studies using triplet regimens and even the addition of immunotherapy have begun to shift the paradigm of systemic therapy. Molecular therapies have recently received US FDA approval for second-line treatment for patients harboring actionable genomic alterations. This review focuses on the multidisciplinary approach to the treatment of ICC with an emphasis on molecular targeted and systemic therapy.

Original languageEnglish (US)
Pages (from-to)2607-2621
Number of pages15
JournalFuture Oncology
Volume19
Issue number39
DOIs
StatePublished - Dec 1 2023

Keywords

  • Intrahepatic cholangiocarcinoma
  • adjuvant therapy
  • immunotherapy
  • molecular targeted therapy
  • neoadjuvant therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Molecular targeted and systemic therapy for intrahepatic cholangiocarcinoma: a multi-disciplinary approach'. Together they form a unique fingerprint.

Cite this